Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/126514
Clinical perspectives on human genetic screening to prevent nevirapine toxicity
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Nevirapine is one of the most extensively prescribed antiretroviral drugs worldwide. However, a concern is increased risk for severe toxicity when antiretroviral-naive individuals with higher CD4 T-cell counts initiate nevirapine-containing regimens. Several genetic variants are associated with nevirapine toxicities. The authors used data from a previous study to anticipate potential consequences of genetic screening to prevent nevirapine adverse events. That study enrolled cohorts of African, Asian and European descent in 11 countries, including 276 patients who had experienced severe cutaneous and/or hepatic adverse events with nevirapine-containing regimens and 587 matched nevirapine-tolerant controls. Associations were identified with HLA-Cw*04, HLA-B*35, HLA-DRB*01 and CYP2B6 516G>T (rs3745274); however, positive predictive values for these genetic markers were low, and most nevirapine-associated adverse events occurred in patients without these markers. Unless better genetic predictors are identified, nevirapine toxicity is best avoided by continuing to follow current prescribing guidelines that are based largely on CD4 T-cell criteria.
Subject
Subject (English)
Citation
Citation
HAAS, David W., et al. Clinical perspectives on human genetic screening to prevent nevirapine toxicity. Personalized Medicine. 2012. Vol. 9, num. 7, pags. 773-782. [consulted: 12 of June of 2026]. Available at: https://hdl.handle.net/2445/126514